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Abstract A mammalian expression vector directing the synthesis of a cytoplasmic single chain Fv version of the Y13-259 anti-Ras antibody was 
constructed and co-transfected into the human lymphoid cell line Jurkat together with a reporter construct containing the bacterial gene for 
chloramphenicol acetyl transferase under the transcriptional control of several copies of the binding site for the transcription factor NF-AT. The 
Ras specific antibody interferes with NF-AT activation upon direct activation f the T-cell antigen receptor, whereas activation by direct protein 
kinase C stimulation is less sensitive to the anti-Ras antibody. Furthermore, the observed inhibition is dependent  the ratio of antibody to reporter 
plasmid utilized in the transfection experiments. 
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I. Introduction 
The involvement of Ras in T-cell antigen receptor (TCR) 
mediated signal transduction has recently been demonstrated. 
Activation of the receptor by a specific antigen in association 
with lymphokine stimulation activate resting T-cells. An indis- 
pensable step in this process is the induction of interleukin-2 
(IL-2) and interleukin-2 receptor expression, which leads to 
autocrine growth stimulation [1]. Analysis of the IL-2 promoter 
revealed that the NF-AT transcription factor is essential for 
IL-2 expression. It has previously been reported that a synthetic 
promoter containing several copies of the binding site for NF- 
AT is activated by TCR stimulation [2]. 
We have previously demonstrated that activated Ras protein, 
at least in part, can substitute for direct activation of protein 
kinase C (PKC) by the phorbol ester, PMA [3]. Furthermore, 
we have shown that the dominant negative Asn ~7 mutant of 
Ras, which is deprived of activity and inhibits endogenous Ras 
[4], abolishes phytohemagglutinin (PHA) activated TCR in- 
duced stimulation of NF-AT promoter [3]. 
Alternative methodologies to interfere with the intracellular 
function of a biological component have been developed, which 
involve expression of an antibody intracellularly to allow it o 
interfere with e biological ctivity of its antigen. Recently the 
expression i  the secretory compartment of an anti-HIV-1 anti- 
body gene was shown to inhibit correct processing of the HIV-1 
gpl60 protein, and thus block HIV-1 production [5]. Addition- 
ally, this technique has been applied to plants on the expression 
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of anti-artichoke mottled crinkle virus single chain Fv antibody 
(ScFv) which reduces infection incidence and delays ymptom 
development. [6]. 
To examine the feasibility of extending this experimental 
strategy to non-secretory compartments of mammalian cells 
and to compare its potential to that of a well established dom- 
inant negative mutant, we attempted the expression of an anti- 
Ras antibody molecule in the cytoplasm of Jurkat cells, mRNA 
microinjection experiments have shown that this antibody pro- 
tein is correctly folded and interacts with Ras protein in the 
cytoplasm of Xenopus oocytes [7]. Here we show that trans- 
fected anti-Ras antibody interferes with TCR induced signal 
transduction and has an effect comparable to that of the 
AsnlTRas mutant. We also report that the specificity of the 
inhibition is similar to that of the dominant negative Ras mu- 
tant as also the anti-Ras ntibody less efficiently interferes with 
signal transduction following direct PKC stimulation. Finally 
we show that blocking Ras signalling by the cytoplasmic anti- 
Ras ScFv is dependent on the quantities of the ScFv expression 
vector utilised. 
2. Experimental 
2.1. Plasmids 
The anti-Ras ScFv expression vector, pcDNAI/ScFvYI3.259, was 
constructed as follows. The Y13.259-ScFv gene was subcloned from the 
secretory bacterial expression vector, p3JF4 [8], as a PstI-BamHI frag- 
ment and inserted into the leaderless ScFv expression vector, pJM1. 
This plasmid has been generated by deleting the pelB secretory leader 
sequence ofp3JF4, thus yielding a leaderless 5' of the ScFv gene (cor- 
responding to the amino acid sequence Met Gin Val Gin ). The leader- 
less Y 13.259-ScFv gene was subsequently cloned into the mammaliam 
expression vector, pcDNAlamp (Invitrogen) as a HindlII-BamHI 
fragment, producing pcDNAI/ScFv-Y13.259. 
NF-AT/CAT contains a trimer of the NF-AT binding site upstream 
of the CAT gene [2]. CMV/gal (Clontech) contains the gen  encoding 
fl-galactosidase under the control f the CMV promoter. 
2.2. Cell culture, transfections, immunofluorescence and CAT assays 
COS-7 cells were maintained i  DMEM supplemented with 2 mM 
L-glutamine and 10% heat-inactivated f tal calf serum (Gibco). COS 
cells were transfected with 2/1g of the relevant pcDNAI/ScFv vector 
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using the Lipofectin Transfection Kit (BRL) according to the manufac- 
turers instructions. After 48 h cells were fixed as described [9] and 
probed with the mouse anti-myc.tag ntibody, 9El0. Specific binding 
was evidenced using a FITC conjugated anti-mouse Ig antibody 
(Amity). 
Jurkat cells were mantained in RPM1 supplemented with 2 mM 
L-glutamine and 10% heat-inactivated fetal calf serum (Boehringer, 
Mannheim). Transfections were carried out as described [3] using 106 
cells per sample and 0.4/zg NF-AT/CAT and up to 2/tg anti-ras ScFv 
plasmid DNA or the same amount of control vector per sample. To 
minimize variability among samples activations were carried out on 
aliquots of a single pool of transfected cells. In addition all samples were 
in duplicate. A plasmid encoding fl-galactosidase (0.4 pg/sample) was 
included in all cotransfections a  a control of transfection efficiency. 
Cells were allowed to recover for 22 h, then activated either with 2/lg/ml 
PHA (Wellcome Diagnostics, Dartford, UK) or with a combination of
10 ng/ml PMA (Sigma) and 100 ng/ml A23187 (Boehringer, 
Mannheim). Cells were collected 8 10 h after activation and processed 
for CAT assays as described [10]. Equal amounts of proteins, as deter- 
mined using the BCA kit from Pierce (Rockford, IL), were used. CAT 
assays using [t4C]chloramphenicol were carried out according to 
Gorman et al. [10]. Thin layer chromatograms were scanned and chlor- 
amphenicol conversion was quantitated using a phosphorimager (Mo- 
lecular Dynamics, Sunnyvale, CA). CAT values were normalized to 
fl-galactosidase values to correct for variations in transfection effi- 
ciency. 
3. Results 
The Ras specificity of the Y13.259-ScFv was demonstrated 
after its expression from the vector 3JF4 as a secretory protein 
in bacteria [8]. However, we considered that the bacterial secre- 
tory leader sequence (pelB) in this ScFv vector would not en- 
sure cytoplasmic expression in mammalian cells. To obtain 
cytoplasmic expression of the ScFv in mammalian cells we 
deleted the bacterial secretory leader and constructed a leader- 
less Y13.259-ScFv gene encoding a protein in which the amino 
terminal is Met Gin Val Gin; Gin corresponds to amino acid 
number 1 of the heavy chain as defined by Kabat et al. [11]. The 
leaderless Y 13.259-ScFv gene was inserted into the mammalian 
expression vector pcDNAlamp (Invitrogen) under the tran- 
scriptional control of the cytomegalovirus promoter (Fig. 1). 
Expression and correct cytoplasmic localisation of the lead- 
erless ScFv protein was assessed in transiently transfected COS- 
7 cells. The ScFv protein carries the C-terminal myc tag which 
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Fig. 1. Mammalian ScFv expression vector. The regions encompassing 
the CMV promoter, the variable regions (VH and VL) and the linker 
peptide, the myc-tag and the SV40 polyA sequence are shown. Lines 
indicate non relevant vector sequences. H: HindllI; P: PstI; B: BamHI. 
is specifically recognised by the monoclonal antibody, 9El0 
[12]. Indirect immunofluorescence against the Y13.259-ScFv 
expressed in COS cells yields a staining (Fig. 2A) which is 
clearly distinct from that of a secretory antibody (Fig. 2B), thus 
indicating that the protein is correctly expressed outside the 
secretory compartment. However, unlike the secretory anti- 
body the intracellular ScFv is only seen in a low procentage of 
the transfected cell population. This phenomenon may reflect 
specific processing of the immunoglobulin chains and subse- 
quent loss of the myc-tag [13]. 
To investigate whether that the cytoplasmic anti-Ras ScFv 
can interfere with Ras dependent signalling we utilised the 
human lymphoid cell line Jurkat in which T-cell antigen recep- 
tor signalling requires Ras activity. A reporter plasmid contain- 
ing the bacterial gene for chloramphenicol acetyl transferase 
under the control of several copies of the binding site for the 
transcription factor NF-AT can be activated in Jurkat cells by 
treatment with the TCR agonist phytohemagglutinin and in- 
duction assessed espite the low number of transfected cells. 
Cotransfection of the reporter construct with a construct capa- 
ble of expressing the dominant inhibitor mutant of Ras, 
AsnlTRas [4], results in inhibition of TCR-induced CAT activity 
[3]. Fig. 3 shows the results of CAT assays of cells co-trans- 
fected with the reporter construct and an expression vector 
directing the expression of the leaderless anti-Ras ScFv. The 
levels of CAT activity after PHA stimulation was significantly 
lower (55%) than in the corresponding control cells (Fig. 3), 
demonstrating that the Y13.259 ScFv interferes with the TCR 
activation of NF-AT in a mode similar to that of Asn17Ras. 
Expression of the Y13.259 also reduced activation of the re- 
A B 
Fig. 2. Immunofluoresence of antibody expressing cells. COS cells were transfected with the leaderless pcDNAI/ScFv vector (panel A) or an antibody 
with the wildtype Ig secretory leader sequence (panel B). Cells were assayed for intracellular localisation of the expressed antibody protein 48 h after 
transfection by indirect immunofluresence using the the anti-myc.tag ntibody as decribed in section 2. 
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Fig. 3. Inhibition of TCR dependent NF-AT activation by overexpres- 
sion of anti-ras ScFv. Acetylated ['4C]chloramphenicol in thin layer 
chromatograms of CAT assays of Jurkat cells cotransfected with NF- 
AT/CAT (0.4/tg/sample) and anti-rasScFv plasmid DNA (1.7/~g/sam- 
pie) and activated with either PHAor a combination f PMA (10 ng/ml) 
and A23187 (100 ng/ml) as indicated. Values are expressed as perc nt 
of control samples cotransfected with the same amount of mpty vector 
plasmid. Data are average and standard deviation from two independ- 
ent experiments each with duplicate samples. In one of these experi- 
ments, a plasmid containing a  irrelevant ScFv (anti-lysozyme) was 
tested in parallel with the Ras ScFV. 
porter by phorbol myristate acetate in combination with the 
calcium ionophore A231287 but the effect was less dramatic 
(Fig. 3). Thus, the effect of the anti-Ras ScFv parallels that of 
Asn ]TRas [3] indicating that the Y 13.259 ScFv specifically inter- 
feres with the activity of the endogenous Ras protein. 
Unfortunately, it was not possible to directly assess the levels 
of the ScFv in the transfected Jurkat cells most probably due 
to the very low transfection efficiency of these cells and the 
potential processing of the cytoplasmic ScFv. Nevertheless, the 
finding that inhibition of PHA stimulated TCR activation of 
NF-AT is directly dependent on the amount of anti-Ras ScFv 
expressing vector included in the co-transfection experiment 
further strengthens the notion that the observed inhibition is 
Ras-specific. Fig. 4 illustrates that PHA stimulated CAT activ- 
ity is reduced more than 50% in cells co-transfected with a 
5-fold excess of the inhibitory ScFv plasmid with respect to the 
NF-AT/CAT reporter construct. Further, an inhibitory effect 
can be detected using as little as 0.5/tg of the anti-Ras ScFv 
per transfection, representative of a reporter plasmid/ScFv 
plasmid ratio as low as 1. 
4. Discussion 
In this study we describe the first application f new method 
to interfere with a given biological activity in living mammalian 
cells. We have expressed the single chain Fv derivative of the 
neutralising anti-Ras antibody Y13-259 as a cytoplasmic pro- 
tein. The Ras specific ScFv strongly interferes with signal 
transduction through endogenous Ras protein. Our results 
demonstrate hat the ScFv mediated inhibition parallels that 
observed with the dominant negative Asn17Ras mutant in that 
it is considerably more potent in interfering with PHA than 
PMA/A23187 induced signal transduction. Furthermore, we 
observe that the inhibition isdependent on the quantity of ScFv 
DNA utilised in the transfection experiments. 
We were unable to completely abolish the TCR signalling 
through Ras, as it is unlikely that all cells which took up the 
NF-AT reporter plasmid also took up the ScFv construct. 
Additionally, it is not known whether at the cellular level there 
is a linear relation between Ras activity and NF-AT induction, 
or alternatively that NF-AT activity is only induced in cells 
where Ras activity exceeds a given threshold. One might spec- 
ulate that different Ras effects necessitate different levels of Ras 
activity. 
Dominant negative mutations exert their inhibitory action 
through a competitive interaction with accessory components 
vital for the activity of the inhibited protein but possibly also 
for other cellular processes. Therefore, it cannot be excluded 
that the approach of utilising dominant negative mutations may 
provide somewhat misleading results. In contrast, he antibody 
mediated neutralisation results from a direct interaction be- 
tween the antibody and the Ras protein, thus excluding this 
possible source of error. 
Intracellular immunisation mediated by antibodies xpressed 
in the cytoplasm may provide a very powerful research tool 
which, contrary to the methologies of anti-sense RNA, 
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Fig. 4. Dose-response inhibition of TCR induced NF-AT activation by 
anti-ras ScFv. Acetylated ['4C]chloramphenicol in thin layer chromato- 
grams of CAT assays of Jurkat cells cotransfected with NF-AT/CAT 
(0.4/ag/sample) and increasing amounts of anti-rasScFv plasmid DNA 
as shown. Control DNA was added to reach a total amount of 
2 gg/sample of expression plasmid DNA. Cells were activated with 
PHA. The figure shows the average and standard deviation calculated 
on duplicate samples. 
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ribozymes and dominant negative mutants does not necessitate 
substantial and individual optimisation, but is based on the 
expression of one protein from standard vectors. In fact, the 
general nature of this strategy resides in the characterisation, 
cloning and expression of one single chain Fv. 
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